Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].

Matsumoto T, Takeji S, Asagi A, Kajiwara T, Nishina T, Hori S, Ikeda Y, Nadano S, Iguchi H.

Nihon Shokakibyo Gakkai Zasshi. 2011 Dec;108(12):2003-9. Japanese.

PMID:
22139487
2.

Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.

Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S, Yokosuka O, Tanaka K, Moriyasu F, Nakamori S, Sato T.

Jpn J Clin Oncol. 2011 Aug;41(8):953-8. doi: 10.1093/jjco/hyr090. Epub 2011 Jun 29.

PMID:
21715364
3.

S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.

Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS.

Jpn J Clin Oncol. 2009 Jan;39(1):49-53. doi: 10.1093/jjco/hyn126. Epub 2008 Dec 5.

PMID:
19060295
4.

A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.

Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K.

Oncology. 2005;69(5):421-7. Epub 2005 Nov 25.

PMID:
16319514
5.

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.

Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9. doi: 10.1007/s00280-008-0741-7. Epub 2008 Apr 9.

PMID:
18398614
6.

A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.

Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M.

Oncology. 2009;77(5):300-3. doi: 10.1159/000259616. Epub 2009 Nov 17.

PMID:
19923869
7.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
8.

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.

Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH.

Cancer Chemother Pharmacol. 2009 Sep;64(4):707-13. doi: 10.1007/s00280-008-0918-0. Epub 2009 Jan 17.

PMID:
19151975
9.

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).

Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T.

Cancer Chemother Pharmacol. 2012 May;69(5):1197-204. doi: 10.1007/s00280-012-1822-1. Epub 2012 Jan 17.

PMID:
22249272
10.

Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.

Suzuki S, Ozaki Y, Saida S, Kaji S, Koike N, Harada N, Hayashi T, Suzuki M.

Hepatogastroenterology. 2013 Jun;60(124):916-20. doi: 10.5754/hge121235. Epub 2013 Mar 11.

PMID:
23478143
11.

Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.

Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C.

Jpn J Clin Oncol. 2015 Dec;45(12):1122-30. doi: 10.1093/jjco/hyv141. Epub 2015 Oct 30.

PMID:
26518328
12.

[A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].

Hoshino H, Takeda Y, Nagano H, Nakamori S, Kobayashi S, Eguchi H, Marubashi S, Tanemura M, Kitagawa T, Umeshita K, Monden M, Doki Y, Mori M.

Gan To Kagaku Ryoho. 2009 Nov;36(12):2419-21. Japanese.

PMID:
20037442
13.

Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.

Sudo K, Ishihara T, Hirata N, Ozawa F, Ohshima T, Azemoto R, Shimura K, Nihei T, Nishino T, Nakagawa A, Nakamura K, Hara T, Tada M, Mikata R, Tawada K, Yokosuka O, Nakaji S, Yamaguchi T.

Cancer Chemother Pharmacol. 2014 Feb;73(2):389-96. doi: 10.1007/s00280-013-2368-6. Epub 2013 Dec 10.

PMID:
24322377
14.

Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Nakagawa N, Sueda T.

J Surg Oncol. 2012 Aug 1;106(2):174-80. doi: 10.1002/jso.23068. Epub 2012 Feb 13.

PMID:
22331838
15.

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.

Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH.

Cancer Chemother Pharmacol. 2010 Feb;65(3):527-36. doi: 10.1007/s00280-009-1059-9. Epub 2009 Jul 4.

PMID:
19578850
16.

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M.

J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1.

PMID:
23547081
17.

[A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].

Iwauchi T, Amano R, Ohira G, Nakamoto K, Doi Y, Yamada N, Ohira M, Hirakawa K.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2373-5. Japanese.

PMID:
21224577
18.

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.

Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Hollerbach C, Endlicher E.

Br J Cancer. 2009 Apr 7;100(7):1032-6. doi: 10.1038/sj.bjc.6604983. Epub 2009 Mar 17.

19.

A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.

Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K.

Br J Cancer. 2012 Jun 5;106(12):1934-9. doi: 10.1038/bjc.2012.183. Epub 2012 May 3.

20.

[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].

Yoshida Y, Sugawara N, Minami T, Iwata N, Ikeda K, Endoh T, Sasano H.

Nihon Shokakibyo Gakkai Zasshi. 2013 Apr;110(4):660-8. Japanese.

PMID:
23558130

Supplemental Content

Support Center